MacroGenics | MGNX - Gross Profit On Sales

MacroGenics reported $71.31M in Gross Profit on Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Gross Profit On Sales Change
Amgen AMGN:US USD 5.09B 28M
AstraZeneca AZN:LN USD 8.7B 168M
Biogen BIIB:US USD 1.97B 65.9M
Bristol Myers Squibb BMY:US USD 8.89B 21M
Daiichi Sankyo 4568:JP JPY 242.5B 207M
Eli Lilly And LLY:US USD 5.75B 391.2M
Gilead Sciences GILD:US USD 5.99B 346M
Johnson & Johnson JNJ:US USD 15.94B 56M
Karyopharm Therapeutics KPTI:US USD 31.71M 3.45M
MacroGenics MGNX:US USD 71.31M 32.72M
Merk MRK:US USD 10.47B 610M
Pfizer PFE:US USD 14.47B 2.08B
Puma Biotechnology PBYI:US USD 48.84M 4.23M
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Roche Holding ROG:VX 22.04B 696M
Seattle Genetics SGEN:US USD 419.94M 17.76M